Rystiggo (rozanolixizumab) is now listed on the Pharmaceutical Benefits Scheme (PBS) for generalised Myasthenia Gravis (gMG) patients who are AChR antibody positive.* 

Rystiggo is the first neonatal Fc receptor (FcRn) inhibitor available via the PBS for our patient community. This is a fantastic milestone for us because it expands our treatment options. 

In fact, it is a big year for new and innovative therapies for Myasthenia. Rystiggo follows the PBS listings of 2 complement inhibitors earlier this year. We are experiencing a revolution in research and treatments for MG and these treatment options need to be available and accessible.

Amongst the excitement of new therapies, the MAA understood that patients had unmet needs in controlling MG symptoms and many were limited in doing daily activities. Many of us also wanted a more manageable or more flexible treatment. 

Thanks to your participation in surveys and sharing your feedback, we presented a strong case for the need to reduce the burden of living with MG and improve our quality of life. 

While it was a long and complex process, many stakeholders worked together to achieve this positive outcome. The MAA thanks everyone involved, especially the sponsoring company for their work through the PBAC process and for working with us to better understand the new treatment landscape. 

Doctors, healthcare professionals and patients are all learning about the new treatment options. The MAA will bring information to you as soon as the doctors are ready. Subscribe for updates at https://myastheniaalliance.org.au and save the date for the national MG patient conference in Brisbane on 31st October 2026. 

The MAA’s advocacy work will continue, to ensure we capture real-world data about treatment use and impacts, but also to ensure sub-groups of MG patients, including non-AChR+, ocular MG patients and children, can access the best possible treatment for their individual condition.

A reminder to please talk to your healthcare professional to discuss your treatment options and plan, including any possible side effects or risks. 

If you have any questions or feedback to share with the MAA, please contact us by emailing info@mgaq.org.au or info@myasthenia.org.au, or calling 1800 802 568.

*The MAA and state associations do NOT provide medical advice regarding medications or treatments for individuals. Decisions about whether new treatments will be suitable for you as a patient must be discussed with your doctor or health professional.